Major Preclinical CRO / CDMO – Cell and Gene Therapy, Advanced Therapy Testing

Bankruptcy Sale: USBC Southern District of Ohio. Petition No: 25-52140 | In re: AmplifyBio, LLC

Bid Deadline for Real Estate, Equipment (Entirety or Bulk Package Bids) and Intellectual Property: August 15, 2025 by 12:00 PM EST

This world-class research and development facility – owned and occupied by AmplifyBio – is a purpose-built facility for preclinical CRO (Contract Research Organization) services. Designed to support pharmaceutical, biotechnology and medical device development, the facility is focused on toxicology, safety, pharmacology and bioanalytic characterization to advance therapeutic innovation. With integrated, specialized laboratories, an on-site surgical suite and a 64-room (34,500± SF) vivarium featuring a one-way traffic flow design, the property is ideally suited for companies seeking a turnkey solution for regulated, high-complexity research.

The property features a highly secured entrance, ensuring enhanced privacy for sensitive research. With its sophisticated infrastructure and comprehensive capabilities, this facility represents a rare opportunity to acquire a premier building tailored to the evolving needs of modern biomedical and clinical research.